Key Takeaways
- • Healthcare private equity achieved record global deal value in 2025, powered by large transactions despite Q2 slowdowns in North America and Asia-Pacific regions.
- • Deal count reached the second-highest annual total on record, with strength demonstrated across all deal size categories, indicating broad-based market participation.
- • Provider and biopharma sectors anchored dealmaking activity, while healthcare IT continued gaining share of overall healthcare transaction volume.
- • Sponsor-to-sponsor transactions returned as a meaningful activity driver, reflecting renewed confidence among existing PE investors in market fundamentals despite macroeconomic headwinds.
- • Artificial intelligence and technology infrastructure emerged as critical value-creation drivers, requiring investors to demonstrate operational sophistication and conviction in differentiated playbooks to compete for assets in an increasingly intense competitive environment.
Summary
Healthcare private equity entered 2026 on a foundation of momentum, having achieved record global deal value in 2025 according to Bain & Company's midyear update. The sector overcame a notable Q2 slowdown in both North America and Asia-Pacific to deliver strong annual results, with deal count posting the second-highest total on record. This performance reflects sustained investor confidence in healthcare fundamentals despite broader macroeconomic uncertainty affecting other sectors.
The breadth of 2025 activity extended across all deal size categories, indicating that momentum was not concentrated among megadeals alone. Provider and biopharma sectors led transactional activity, anchoring dealmaking volumes as traditional healthcare subsectors maintained their centrality to PE strategy. Healthcare IT, however, demonstrated accelerating momentum, capturing an expanding share of overall healthcare transaction volume—a structural shift that reflects investor conviction around digital transformation and technology-enabled value creation within healthcare ecosystems.
A significant trend reversal emerged through the return of sponsor-to-sponsor activity, where established PE investors transitioned portfolio companies or stakes to other sponsors. This activity signals deepening confidence among institutional PE players in market valuations and operational trajectories, as secondaries and continuation funds increasingly drove transaction flow. The resumption of sponsor-to-sponsor deals suggests that leading managers believe sufficient value remains capturable through operational intervention and strategic repositioning.
Looking forward from mid-2026, Bain's analysis emphasizes that AI and technology infrastructure have become non-negotiable components of healthcare PE value creation. Investors must demonstrate operational sophistication beyond traditional cost management, integrating advanced analytics, automation, and digital capabilities into portfolio company playbooks. Competition for high-quality assets remains intense, requiring managers to develop differentiated conviction around their specific value-creation approaches to generate outsized returns in an increasingly crowded market.
The breadth of 2025 activity extended across all deal size categories, indicating that momentum was not concentrated among megadeals alone. Provider and biopharma sectors led transactional activity, anchoring dealmaking volumes as traditional healthcare subsectors maintained their centrality to PE strategy. Healthcare IT, however, demonstrated accelerating momentum, capturing an expanding share of overall healthcare transaction volume—a structural shift that reflects investor conviction around digital transformation and technology-enabled value creation within healthcare ecosystems.
A significant trend reversal emerged through the return of sponsor-to-sponsor activity, where established PE investors transitioned portfolio companies or stakes to other sponsors. This activity signals deepening confidence among institutional PE players in market valuations and operational trajectories, as secondaries and continuation funds increasingly drove transaction flow. The resumption of sponsor-to-sponsor deals suggests that leading managers believe sufficient value remains capturable through operational intervention and strategic repositioning.
Looking forward from mid-2026, Bain's analysis emphasizes that AI and technology infrastructure have become non-negotiable components of healthcare PE value creation. Investors must demonstrate operational sophistication beyond traditional cost management, integrating advanced analytics, automation, and digital capabilities into portfolio company playbooks. Competition for high-quality assets remains intense, requiring managers to develop differentiated conviction around their specific value-creation approaches to generate outsized returns in an increasingly crowded market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.